Human positron emission tomography studies of brain neurokinin 1 receptor occupancy by aprepitant

Arai, 1986, Regional distribution of neuropeptide K and other tachykinins (neurokinin A, neurokinin B and substance P) in rat central nervous system, Brain Res, 399, 240, 10.1016/0006-8993(86)91514-3 Bergström, 2000, Brain uptake and receptor binding of two (11C)-labeled selective high affinity NK1-antagonists, GR203040 and GR205171—PET studies in rhesus monkey, Neuropharmacology, 39, 664, 10.1016/S0028-3908(99)00182-3 Brodin, 1987, Effects of subchronic treatment with imipramine, zimelidine and alaproclate on regional tissue levels of substance P and neurokinin A/neurokinin B-like immunoreactivity in the brain and spinal cord of the rat, Neuropharmacology, 26, 581, 10.1016/0028-3908(87)90151-1 Campos, 2001, Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone, J Clin Oncol, 19, 1759, 10.1200/JCO.2001.19.6.1759 Carberlotto, 2003, Neurokinin 1 receptor and relative abundance of the short and long isoforms in the human brain, Eur J Neurosci, 17, 1736, 10.1046/j.1460-9568.2003.02600.x Chawla, 2003, Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy induced nausea and vomiting, Cancer, 97, 2290, 10.1002/cncr.11320 Duffy, 2002, Correlation of neurokinin (NK) 1 receptor occupancy in gerbil striatum with behavioral effects of NK1 antagonists, J Pharmacol Exp Ther, 301, 536, 10.1124/jpet.301.2.536 Hargreaves, 2002, Imaging substance P receptors (NK1) in the living human brain using positron emission tomography, J Clin Psychiatry, 63, 18 Hesketh, 2003, Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists, Eur J Cancer, 39, 1074, 10.1016/S0959-8049(02)00674-3 Hietala, 1995, Presynaptic dopamine function in striatum of neuroleptic-naive schizophrenic patients, Lancet, 346, 1130, 10.1016/S0140-6736(95)91801-9 Hökfelt, 1987, Distribution of neuropeptides with special reference to their coexistence with classical transmitters, 401 Huskey, 2003, Brain penetration of aprepitant, a substance P receptor antagonist, in ferrets, Drug Metab Dispos, 31, 785, 10.1124/dmd.31.6.785 Kenakin, 1998 Kramer, 1998, Distinct mechanism for antidepressant activity by blockade of central substance P receptors, Science, 281, 1640, 10.1126/science.281.5383.1640 Mantyh, 1984, Substance P receptors, Brain Res, 307, 147, 10.1016/0006-8993(84)90470-0 Navari, 1999, Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist, N Engl J Med, 340, 190, 10.1056/NEJM199901213400304 Patel, 2003, Aprepitant—a novel NK1 receptor antagonist, Expert Opin Pharmacother, 4, 2279, 10.1517/14656566.4.12.2279 Pioro, 1990, Distribution of substance P-and enkephalin-immunoreactive neurons and fibers, 1051 Poli-Bigelli, 2003, Addition of the oral NK1 antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy induced nausea and vomiting, Cancer, 97, 3090, 10.1002/cncr.11433 Rupniak, 1997, In vitro and in vivo predictors of the anti-emetic activity of tachykinin NK1 receptor antagonists, Eur J Pharmacol, 326, 201, 10.1016/S0014-2999(97)85415-5 Solin O, Eskola O, Hamill T, Bergman J, Lehikoinen P, Grönroos T, et al (in press): Synthesis of and characterisation of a potent, selective, radiolabeled substance-P antagonist (SPA) for NK1 receptor quantitation: ([18F]SPA-RQ). Mol Imaging Biol Talbot, 2002, The role of in vivo molecular imaging with PET and SPECT in the elucidation of psychiatric drug action and new drug development, Eur Neuropsychopharmacol, 12, 503, 10.1016/S0924-977X(02)00099-8 Van Belle, 2002, Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonist, L-758,298 and MK-869, Cancer, 94, 3032, 10.1002/cncr.10516 Wong, 1986, Quantification of neuroreceptors in the living human brain. I. Irreversible binding of ligands, J Cereb Blood Flow Metab, 6, 137, 10.1038/jcbfm.1986.27